A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols

International Journal of Biological Markers

Volumn 12, Issue 1, 1997, Pages 6-14

  Grebenschikov, N ^a   Geurts Moespot, A ^a   De Witte, H ^a   Heuvel, J ^a   Leake, R ^b   Sweep, F ^a   Benraad, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Chicken Ab; Immunoassay compared; Plasminogen activators

Indexed keywords

ENZYME ANTIBODY; HORSERADISH PEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKER; UROKINASE;

ANIMAL EXPERIMENT; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; CYTOSOL; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; NONHUMAN; QUALITY CONTROL;

EID: 0030916215     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200102     Document Type: Article

References (26)

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266.
2. Duffy MT, O'Grady P, Devaney D, O'Siorain L, Fenelly JJ, Lijnen HJ. Urokinase plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report. Cancer 1988; 62: 531-3.
3. Jänicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78.
4. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 predict poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-6.
5. Spyratos F, Martin PM, Hacène K, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 1992; 84: 1266-72.
6. Casslén B, Åstedt B. The plasminogen activation system in ovarian carcinomas. Fibrinolysis 1992; 6 (Suppl. 4): 65-9.
7. Ganesh S, Sier CF, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065-71.
8. Pedersen H, Brünner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5.
9. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 1994; 151: 16-20.
10. Yamashita J, Ogawa M, Yamashita S, et al. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 1993; 68: 524-9.
11. Munch M, Heegard CW, Andreasen PA. Interconversion between active, inert and substrate forms of denaturated/ refolded type-1 plasminogen activator inhibitor. Biochimica et Biophysica Acta 1993; 1202: 29-37.
12. Polson A, Coetzer T, Kruger J, von Maltzahn E, van der Merwe KJ. Improvements in the isolation of IgY from the yolks of eggs laid by immunized hens. Immunol Invest 1985; 14: 323-7.
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
14. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second EORTC workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980; 16: 1513-5.
15. Davies C. Concepts: Correlation and method comparison. In: Wild D, ed. The immunoassay handbook, 1st ed. New York: Stockton Press, 1994: 83-116.
16. Ekins RP. The precision profile: its use in assay design, assessment and quality control. In: Hunter WM and Corrie JET, eds. Immunoassays for clinical chemistry, 2nd ed. Edinburgh: Churchill - Livingstone, 1983: 76-105.
17. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983; 21: 709-20.
18. Passing H, Bablok W. Comparison of several regression procedures for method comparison studies and determination of sample sizes. Application of linear regression procedures for method comparison studies in clinical chemistry, Part II. J Clin Chem Clin Biochem 1984; 22: 431-45.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1: 307-10.
20. Butler JE, Ni L, Nessler R, et al. The physical and functional behavior of capture antibodies adsorbed on polystyrene. J Immunol Methods 1992; 150: 77-90.
21. Butler JE, Ni L, Brown WR, et al. The immunochemistry of sandwich ELISAs - VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denaturated by passive adsorption. Mol Immunol 1993; 30: 1165-75.
22. Zeiss CR, Pruzansky JJ, Patterson R, Roberts M. A solid phase radioimmunoassay for the quantitation of human reaginic antibody against ragweed antigen E. J Immunol 1973; 110: 414-21.
23. Koertge TE, Butler JE. The relationship between the binding of primary antibody to solidphase antigen in microtiter plates and its detection by the ELISA. J Immunol Methods 1985; 83: 283-99.
24. Benraad TB, Geurts-Moespot J, Gröndahl-Hansen J, et al. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTCl/Biomed-1 workshop. Eur J Cancer 1996; 32A: 1371-81.
25. Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986; 34:27-31.
26. Larsson A, Karlsson-Parra A, Sjöquist J. Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors. Clin Chem 1991; 37: 411-4.